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ABSTRACT
Objective: To test the hypothesis that gouty arthritis
(gout) is a risk factor for incidence of heart failure and
for echocardiographic measures signifying subclinical
heart failure.
Design: Post-hoc, longitudinal and cross-sectional
analyses of a prospective cohort study where data
were collected in 4-year intervals since 1971.
Settings: The population-based Framingham Offspring
Study.
Participants: 4989 adults (mean age 36 years, 52%
women) free of clinical heart failure at baseline.
Outcome measures: Incident heart failure,
echocardiographic measures of left ventricular systolic
dysfunction, dilatation and hypertrophy.
Results: Participants with gout (n¼228) had two to
three times higher incidence of clinical heart failure and
echocardiographic measures of systolic dysfunction
compared with those without. In Cox regression
analyses, gout was associated with an adjusted HR of
1.74 (95% CI 1.03 to 2.93) for incident heart failure
and RRs of 3.70 (95% CI 1.68 to 8.16) for abnormally
low left ventricular ejection fraction and of 3.60 (95%
CI 1.80 to 7.72) for global left ventricle systolic
dysfunction. These risk relationships were consistently
observed in all clinical subgroups. Overall, participants
with gout had greater mortality than those without
(adjusted HR 1.58, 95% CI 1.40 to 1.78). Mortality was
elevated in subgroup of patients with gout and heart
failure (adjusted HR 1.50, 95% CI 1.30 to 1.73)
compared to those with heart failure but without gout.
Conclusion: Gout is associated with increased risk for
clinical heart failure, subclinical measures of systolic
dysfunction and mortality.
INTRODUCTION
Heart failure is a major public health problem
in the USA; about 5 million US adults suffer
from heart failure with an annual incidence of
approximately 550000.
1 Heart failure is asso-
ciated with a high risk of morbidity, mortality
and hospital utilisation.
2 The major risk
factors amenable to intervention are obesity,
hyperlipidaemia, hypertension, diabetes,
alcohol abuse and smoking.
3 Ac o m m o n
antecedent for heart failure, atherosclerosis, is
also an independent risk factor for gouty
arthritis (gout).
4e8 Patients with gout often
use medications such as xanthine oxidase
inhibitors and non-steroidal anti-inﬂamma-
tory drug that can decrease or increase the
risk for heart failure, respectively.
9e13 I
hypothesised that patients with gout will have
a greater risk for clinical heart failure than
would be expected from their risk proﬁle.
Gout affects over 3.5 million Americans
annually.
9 Hyperuricaemia is necessary but
not sufﬁcient for development of gout.
14 15
Gouty arthritis is characterised by periods of
intense inﬂammatory response with lower
grade systemic inﬂammation in the period
between acute attacks.
16 I prospectively
analysed the independent relationship
between gout, left ventricular systolic function
and incident heart failure in participants in
the Framingham Offspring Study (FOS)
Cohort. In addition, I sought to study the link
between gout and all-cause mortality in the
entire cohort and among those who devel-
oped heart failure. Being of observational
design and consequent inability to account for
treatment allocation bias, the analysis of rela-
tionship between gout medications such as
allopurinol and the risk of heart failure was
not included within the scope of the present
study.
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ARTICLE SUMMARY
Article focus
- Gout is a common inﬂammatory arthritis that is
a risk factor for cardiovascular disease in general.
- I hypothesised that gout is a speciﬁc risk factor
for heart failure.
Key messages
- Gout is an independent risk factor for incident
heart failure.
- Among those with heart failure gout increases
the case death.
Limitations
- This study does not address the pathophysio-
logical pathways that link gout to heart failure.
- The impact of gout treatment on heart failure risk
cannot be assessed.
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Open Access ResearchMETHODS
Study cohort and data source and design
The FOS is a longitudinal observational cohort assem-
bled in 1971 and includes 5124 men and women who are
the offspring of the Framingham Heart Study Cohort
and their spouses.
17 All participants provided informed
consent. This study used de-identiﬁed data from the FOS
obtained through the National Heart, Lung and Blood
Institute Limited Access Program that excluded those
who did not provide consent for such data sharing and
those with unique characteristics that were deemed to be
identiﬁable (n¼4989). These individuals were observed
over time by periodic examinations approximately
4 years apart; the latest cycle of data collection being in
2008. Data from the medical review, physical examina-
tions and laboratory testing were used for the present
analysis. This study is registered at http://clinicaltrials.
gov (NCT00005121).
Outcomes
Clinical Heart failure and mortality
Incidence of heart failure was assessed by questionnaires
and by physician interview at the time of follow-up visits.
Clinical heart failure and cause of death data were deter-
mined predetermined criteria, included in box 1.
19 20
Speciﬁcally, the simultaneous presence of either two major
or one major plus two minor criteria, in the absence of
an alternative explanation for the symptoms and signs,
was required to make the diagnosis of heart failure.
Major criteria included the following: paroxysmal
nocturnal dyspnoea, orthopnoea, jugular venous
distension, hepatojugular reﬂux, pulmonary rales,
radiographic evidence of cardiomegaly, acute pulmonary
oedema, third heart sound, central venous pressure
above 16 cm of water and weight loss >4.5 kg during the
ﬁrst 5 days of treatment for suspected heart failure.
Minor criteria included the following: bilateral ankle
oedema, nocturnal cough, dyspnoea on ordinary exer-
tion, hepatomegaly, pleural effusion and heart rate
>120 bpm. Hospital and outpatient records
were reviewed by a panel of three physicians for adjudi-
cation of the heart failure outcomes. There were no
participants with heart failure at baseline.
Mortality data were available through the follow-up
cut-off date. These included death certiﬁcates and the
ﬁnal hospitalisation record where applicable. Informa-
tion on clinical heart failure was validated by medical
chart review. I used all-cause mortality data for our
analyses as there was not sufﬁcient power to analyse by
individual causes of death.
Echocardiographic measures of left ventricle
Echocardiographic evaluation was performed on all the
available participants at visit 6 (w year 24; n¼2337).
Routine transthoracic cardiac echocardiograms with
Doppler colour-ﬂow imaging were performed using a
Sonos 1000 Hewlett-Packard machine (Andover, Massa-
chusetts, USA).
21 M-mode measurements of left
ventricle (LV) dimensions were performed by a leading
edge to leading edge technique according to the
American Society of Echocardiography guidelines.
18 22
Details of echocardiographic measurements including
LV mass, LV end-diastolic internal dimensions, LV wall
thickness and fractional shortening have been
published.
23 Only those echocardiograms deemed to be
of fair or good quality were included in the present
analysis. Echocardiographic metrics were treated as
continuous and as dichotomous (no abnormality/any
abnormality) measures. A validated formula was used to
determine LV mass.
22e24 LV wall thickness was calcu-
lated by adding together the diastolic thicknesses of the
septum and the posterior wall.
23 LV systolic dysfunction
was deﬁned as a fractional shortening of <0.29.
25 In
addition, two-dimensional echocardiography was glob-
ally assessed by the FOS physician for abnormal ejection
fraction and evidence of mild or greater systolic
dysfunction as assessed by visual assessment in multiple
views.
25
Assessment of gout
Gout was deﬁned as a study physician diagnosis and/or
use of allopurinol and other gout medications such as
probenecid and colchicine deﬁnite gouty arthritis.
26
This case deﬁnition is known to have high degree of
reliability,
24 validated using medical records in two large
epidemiological studies.
24 27
Other risk factors of heart failure
Information on obesity measures, blood pressure, serum
lipids, serum glucose, smoking and use of alcohol,
Box 1 Framingham criteria for congestive heart failure
18
Major criteria:
Paroxysomal nocturnal dyspnoea
Jugular venous distention
Pulmonary rales
Increasing heart size on chest x-ray ﬁlm
Acute pulmonary oedema
Third heart sound
Central venous pressure of at least 16 cm H2O
Hepatojugular reﬂux
Weight loss of $4.5 kg in response to diuretics
Autopsy evidence of pulmonary oedema
Minor criteria:
Bilateral ankle oedema
Nocturnal dyspnoea
Dyspnoea on ordinary exertion
Hepatomegaly
Pleural effusion
Decrease in vital capacity by one-third from prior maximum
recorded value
Heart rate $120 bpm
At least 2 major or 1 major plus 2 minor criteria; minor
criteria were included only if they were not attributed to
another disease process.
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Gout and heart failureaspirin, antihypertensive medication and anti-diabetic
medication were collected. Hypertension and diabetes
mellitus were deﬁned as per standard criteria and by the
utilisation of relevant medication.
28 29 For the purpose
of this study, participants with a cardiac murmur at the
time of the ﬁrst study visit were assessed to have valvular
heart disease. These data were validated by medical
record review.
Participants were evaluated for coronary artery disease
at baseline and at subsequent visits by medical history,
clinician assessment and electrocardiogram.
Medications
For all medications, current use and past (without
speciﬁcation of time interval) were assessed at the time
of the study visits. Information on current use was used
for the present study. For our analyses, details of indi-
viduals’ antihypertensive and diabetes therapy, such as
the speciﬁc drug, dosage and duration of treatment,
were not available.
Renal function
Based on history and laboratory examination, study
physician and staff determined the presence or absence
of renal dysfunction. Serum creatinine or other labora-
tory measures of renal function was not available for the
present analysis.
Statistical analysis
There were three main components for the statistical
analysis plan: these included a cohort analysis of gout as
a risk factor for heart failure, a longitudinal mortality
analysis that assessed the links between gout, heart
failure and mortality and ﬁnally a cross-sectional analysis
of visit 6 data that compared the echocardiographic
metrics of those with and without gout. Wherever
applicable, all covariates were used as time varying
covariates whereby the values of these measures were
updated by visits in the statistical models.
Longitudinal analyses for incident heart failure
Longitudinal data analyses addressed the question of
whether gouty arthritis was a risk factor for heart failure.
In these analyses, I used Cox proportional hazards
regression models where observation time started at
baseline or at the time of incident gout and ended on
the earliest of the date of incidence of clinical heart
failure. Observations were censored at the last available
time point in the case of death or loss to follow-up. The
Cox model was chosen for heart failure incidence
analyses since preliminary examination of the data
conﬁrmed the proportionality assumption. The cova-
riates used were selected based on whether they were
known risk factors of heart failure: age, body mass index
and total cholesterol/high-density lipoprotein ratio as
continuous variables and hypertension, body mass index,
renal dysfunction, diabetes, alcohol use and smoking as
categorical variables.
Longitudinal analyses for mortality risk
These analyses used Poisson regression models where
covariates of interest were presence or absence of gouty
arthritis; variables adjusted were as above. Cox models
were not ﬁtted as the proportionality assumptions were
not consistently met.
Cross-sectional analyses for echocardiographic data
For analyses of echocardiographic data, I used cross-
sectional analysis methods as these data were obtained
only on visit 6. Ordinary least squared regression models
were used to compute adjusted mean echocardiographic
measures such as left ventricular thickness. Logistic
regression models were used to adjusted estimate
proportion of participants with gout and without gout
with evidence of left ventricular systolic dysfunction and
low ejection fraction. A Poisson approach was used to
calculate RRs of dichotomous echocardiographic
measures.
30 These RR estimates are more conservative
(smaller magnitude) than would be expected from OR
estimates using logistic regression models.
30 This study was
unsponsored. EK possesses raw data, analysis code and will
be the guarantor of the scientiﬁc integrity of this work. All
analyses were performed using STATA (Release 11).
RESULTS
Heart failure incidence
Data were available for 4989 FOS participants (ﬁgure 1).
Table 1 summarises baseline characteristics of the anal-
ysis groups used for longitudinal and cross-sectional
analyses. None of the participants had heart failure,
renal dysfunction or coronary artery disease at the
baseline visit. There were 157 individuals who used
allopurinol during the course of follow-up; none of these
patients developed heart failure and hence effects of
allopurinol on heart failure could not be analysed. Table
2 compares the baseline characteristics of participants
with gout and without gout within the cohort.
Overall heart failure incidence
The total observation time was 135991 person-years. The
median follow-up time was 15.9 years (IQR 8.1e24.0).
Overall, there were 202 incident cases of heart failure. Of
these, 187 were associated with hospitalisation and 15
were diagnosed and treated in the inpatient settings.
The overall incidence rate (95% CI) was 1.5 (95% CI
1.29 to 1.70) per 1000 person-years. The rates among
men and women were 2.2 (95% CI 1.89 to 2.62) and 0.81
(95% CI 0.62 to 1.04), respectively.
Incidence among participants with gout
Among those with gout, the incidence of heart failure
was 3.5 (95% CI 2.30 to 5.32) per 1000 person-years.
Among men, there were 19 incident cases and among
women, there were three. There were no statistically
signiﬁcant differences in incidence rates between men
(3.6, 95% CI 2.3 to 5.6) and women (3.0, 95% CI 1.0 to
9.2). Since the number of women with gout and heart
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Gout and heart failurefailure were so few, meaningful statistical adjustment in
multivariable regressions was not possible and the data
were combined for both the genders.
Gout and the risk for incident heart failure
Overall, there were 228 participants with gout. There
were relatively few cases of heart failure in the ﬁrst
10 years of follow-up. Figure 2 shows the AaleneNelson
cumulative risk curves for heart failure. The curves for
subjects with and without gout began to diverge at
follow-up year 12 when the mean age of the cohort was
47 years. By year 30 (mean age 66 years), the risk of heart
failure was more than twofold higher in the gout group
than in the non-gout group.
In unadjusted Cox regression models, gout was
associated with an increased risk of heart failure with
a HR of 2.8 (95% CI 1.8 to 4.4). In the multivariable
regression models, adjusting for effects of age, hyper-
tension, total cholesterol/high-density lipoprotein
ratio, renal dysfunction, diabetes, alcohol use, smo-
king and body mass index, gout was associated with an
increased risk for incident heart failure with a HR
1.75 (95% CI 1.04 to 2.95). Valvular heart disease
(ie, presence of heart murmur on clinical examina-
tion) was not signiﬁcantly associated with heart failure
incidence, and this variable was not used for multi-
variable analyses. Gout was a signiﬁcant predictor of
heart failure in the subgroups of patients without
hypertension or diabetes and in those with renal
impairment.
Figure 1 Flow diagram of participants and measurements in
the present study. Data from 135 participants were not
available either because the characteristics are so unique as to
jeopardise de-identiﬁcation process used in the Limited Access
Program or they preferred the data not to be shared with non-
Framingham Offspring Study Investigators.
Table 1 Characteristics of participants included in the analysis
Mean±SD/per cent
For longitudinal analyses
of incident heart failure;
assessed at the ﬁrst visit
For cross-sectional analyses of
echocardiographic measures of
systolic dysfunction; assessed at
visit 6 unless otherwise speciﬁed
Number of participants 4989 2336
Characteristic
Age in years 36610 57610
Proportion of men (%) 46 45
Body mass index (kg/m
2)2 5 64.3 27.064.3
Any current alcohol use (%) 85 62
Proportion of current smokers 63 14.3
Current diuretic users (%) 3.2 7.3
Systolic blood pressure (mm Hg) 120615 126618
Diastolic blood pressure (mm Hg) 78610 7469
Fasting glucose (mg/dl) 94622 101625
Total cholesterol (mg/dl) 195639 206639
LDL cholesterol (mg//dl) 124635 130636
HDL cholesterol (mg/dl) 51615 52616
Total cholesterol/HDL cholesterol ratio 4.261.6 1.760.4
Triglycerides (mg/dl) 91680 1346100
Serum urate at visit 1 (mg/dl) 5.361.3 5.261.3
Renal disease/dysfunction (%)* 3.8 3.08
Diabetes (%)* 1.5 7.5
Valvular heart disease (%)* 7.3 8.1
Current antihypertensive therapy (%) 2.4 24.3
Gout anytime during study (%) 4.6 4.1
*Valvular heart disease was deﬁned for this study as presence of cardiac murmur at baseline. Gout was determined based on physician
diagnosis and/or gout medication use. Hypertension was deﬁned as per JNC 7 guidelines and/or use of antihypertensive medications. Diabetes
was deﬁned as per the American Diabetes Association criteria or use of anti-diabetes medications. Renal disease was assessed by study
physician based on history and study laboratory examination.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Gout and heart failureGout and left ventricular dysfunction
At visit 6, 2237 participants had not developed heart
failure and had echocardiograms of acceptable quality
available for our analysis. The baseline characteristics of
these individuals indicated better health status
compared with those who entered the cohort at baseline
but did not obtain echocardiogram due to attrition or
death (table 1). Those with gout had thicker, wider and
heavier LVs and had worse indices of LV function after
adjustment of covariates (table 3). For the Poisson
regression models where the global assessment of LV
function was the dependent variable and gout along
with the covariates described in table 4 were the inde-
pendent variables, patients with gout had a RR of
3.60 (95% CI 1.80 to 7.18) for systolic dysfunction and
a RR of 3.70 (95% CI 1.68 to 8.16) for low ejection
fraction.
Mortality analyses of the heart failure group
Out of the 22 participants in the gout group who
developed heart failure, 16 (73%) died, whereas among
the 178 participants with heart failure but no gout, 109
(61%) died. Within the gout group, incidence heart
failure was associated with substantially higher mortality
rate at 95/1000 person-years compared with those
without heart failure 8/1000 person-years. Gout was
associated with higher mortality rates in unadjusted and
adjusted analyses, and this was statistically signiﬁcant.
The magnitude of excess mortality risk associated with
gout was not modiﬁed by the presence or absence of
heart failure table 4.
DISCUSSION
Our analysis of data collected on FOS participants indi-
cates that gout is an independent risk factor for
subclinical myocardial dysfunction, incident heart
failure and mortality after incidence of heart failure.
Table 2 Comparison of participants with and without gout
Characteristic
Mean±SD/per cent
No gout, N[4291 Gout, N[228 p Value
Age in years 36610 4069 <0.001
Proportion of men (%) 46 83 <0.001
Body mass index (kg/m
2)2 5 64.3 2864.1 <0.001
Current alcohol use (%) 85 95 <0.001
Proportion of current smokers 63 72 0.003
Current diuretic use (%) 3.2 7 <0.001
Systolic blood pressure (mm Hg) 120615 133617 <0.001
Diastolic blood pressure (mm Hg) 78610 86610 <0.001
Fasting glucose (mg/dl) 94622 104632 <0.001
Total cholesterol (mg/dl) 195639 213638 <0.001
LDL cholesterol (mg//dl) 124635 138634 <0.001
HDL cholesterol (mg/dl) 51615 45614 <0.001
Total cholesterol/HDL cholesterol ratio 4.261.6 5.161.7 <0.001
Triglycerides (mg/dl) 91680 140698 <0.001
Serum urate (mg/dl) 5.361.3 7.361.4 <0.001
Renal disease/dysfunction (%)* 3.8 5.8 0.14
Diabetes (%)* 1.5 3.2 0.06
Valvular heart disease (%)* 7.3 4.4 0.1
Current antihypertensive therapy (%)* 2 8.8 <0.001
*Valvular heart disease was deﬁned for this study as presence of cardiac murmur at baseline. Gout was determined based on physician
diagnosis and/or gout medication use. Hypertension was deﬁned as per JNC 7 guidelines and/or use of antihypertensive medications. Diabetes
was deﬁned as per the American Diabetes Association criteria or use of anti-diabetes medications. Renal disease was assessed by study
physician based on history and study laboratory examination.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Figure 2 NelsoneAalen cumulative risk estimates for heart
failure among those with and without gout (n¼228 and 4761,
respectively) in the Framingham Offspring Study. The number
of participants at risk for heart failure in each group is provided
in two rows. The number of incident cases of heart failure in
each time interval is provided within parenthesis.
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Gout and heart failureThis study adds to the growing body of evidence
suggesting that gout has major consequences on the
cardiovascular system. The cohort studied was large,
events were numerous enough for meaningful analyses
and the subclinical, clinical and mortality outcomes were
well deﬁned. Nevertheless, it is important to keep in
mind that data characteristics of FOS could have affected
generalisability of our results and conclusions. Our risk
estimates may be an underestimate of the true under-
lying risk for gout since I included allopurinol (a drug
with beneﬁcial effect on myocardial systolic function)
use as a case deﬁnition and since there were no heart
failure events among those who took allopurinol.
Misclassiﬁcation of gout diagnosis would have intro-
duced measurement error and reduced the power of this
study, that is, type 2 error. There is a concern for residual
confounding by factors that were not measured such as
the impact of non-steroidal anti-inﬂammatory drugs
often used by patients with gout. Some of the excess risk
I observed could be attributed to this class of drugs
and not to gout per se. In studies that span 3 decades,
competing risks for morbidity and mortality and conse-
quent survivor effects are inevitable. Another important
data limitation was that urate levels were measured only
in the ﬁrst two visits and the relative importance of urate
and gout could not be assessed. Lastly, information on
the duration and severity of gout was not available.
The goutemortality association I have documented is
consistent with prior observations. Studies using data
from administrative databases have suggested that
among patients with pre-existing heart failure, active
gout is associated with 50%e100% excess risk for poor
outcomes such as hospitalisation and death.
31 Tissue
hypoxiada hallmark of heart failuredis a stimulus for
Table 3 Echocardiographic characteristics at the Framingham Offspring Study visit 6 (N¼2337)
Echocardiographic
measure
Adjusted for age and body mass
index
Adjusted for age hypertension,
body mass index, renal
dysfunction, diabetes, alcohol
use, smoking and total
cholesterol/HDL cholesterol ratio
Gout No gout p Value Gout No gout p Value
Mean LV thickness (cm) 2.02 1.89 <0.0001 1.99 1.89 <0.0001
Mean LV fractional shortening (range 0e1) 0.35 0.37 0.006 0.35 0.37 0.005
Mean LV diastolic internal dimension (cm) 5.00 4.79 <0.0001 4.96 4.79 0.003
Mean LV mass (g) 188.51 159.29 <0.0001 182.47 159.58 <0.001
Proportion of participants with systolic
dysfunction (%)*
12.7 3.5 <0.0001 10.0 2.3 0.002
Proportion of participants with low ejection
fraction (%)*
7.7 2.3 0.001 5.3 1.6 0.003
Hypertension was deﬁned as per JNC 7 guidelines and/or use of antihypertensive medications. Diabetes was deﬁned using the American
Diabetes Association criteria or use of anti-diabetes medications.
*Two-dimensional echocardiography was globally assessed by study physician for abnormal ejection fraction and evidence of mild or greater
systolic dysfunction as assessed by visual assessment in multiple views.
HDL, high-density lipoprotein; LV, left ventricle.
Table 4 Mortality analyses by gout and heart failure status in the Framingham Offspring Study using Poisson regressions
(n¼4989)
Number of observations
in the model
RR for death
(95% CI)
Unadjusted estimates
Heart failure vs no heart failure 32267 5.28 (4.89 to 5.69)
Gout vs no gout 32267 1.74 (1.57 to 1.93)
Gout vs no gout among those without heart failure 30774 1.55 (1.34 to 1.76)
Gout vs no gout among those with heart failure 1493 1.24 (1.02 to 1.51)
Adjusted estimates*
Heart failure vs no heart failure 27209 3.73 (3.39 to 4.10)
Gout vs no gout 27209 1.58 (1.40 to 1.78)
Gout vs no gout among those without heart failure 26073 1.50 (1.30 to 1.73)
Gout vs no gout among those with heart failure 1136 1.37 (1.10 to 1.74)
*Adjusted for age, body mass index and total cholesterol/high-density lipoprotein ratio as continuous variables and hypertension, body mass
index, renal dysfunction, diabetes, alcohol use and smoking as categorical variables.
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Gout and heart failurethe production of urate
32; among those with heart
failure, serum urate concentrations are inversely corre-
lated with maximal oxygen uptake and functional
status.
33 Serum urate levels correlate well with circu-
lating markers of inﬂammation and with oxidative stress
in patients with chronic heart failure.
33 34 Indeed, there
is an inverse relationship between serum urate concen-
trations and peripheral blood ﬂow in patients with
chronic heart failure.
35 Serum urate levels can predict
mortality in patients with chronic heart failure.
36 37 In
our study, urate was measured only in ﬁrst two visits.
The pathophysiological pathways that link gout and
myocardial dysfunction are unclear. The two major
categories of heart failure are those caused by hyper-
tension and those caused by atherosclerotic coronary
artery disease. This study cannot assess the relative
contributions of such pathways as the risk factors that
cause atherosclerotic heart disease are collinear with
those for heart failure. Furthermore, gout is known to be
associated with both of these intermediate steps to heart
failure.
38 Hyperuricaemia has been linked to incident
heart failure.
39 Increased serum acid levels may
contribute to the echocardiographic abnormalities
associated with heart failure through effects on endo-
thelial function and inﬂammation. In a small study in
patients with chronic heart failure (n¼55), the concen-
tration of serum uric acid was an independent predictor
of the inﬂammation markers intracellular adhesion
molecule 1, tumour necrosis factor, soluble tumour
necrosis factor receptors and interleukin 6.
34 The
National Health and Nutrition Survey conducted in
former West Germany also showed an association
between serum uric acid concentration and C reactive
protein.
40 Uric acid can inhibit nitric oxide production
by vascular endothelial cells and their proliferation and
migration.
41 Another possibility is that the link might be
mediated through hypertension. In an analysis of
Framingham Study participants who did not have
hypertension, myocardial infarction, heart failure, renal
failure or gout at baseline, serum uric acid levels were an
independent predictor of hypertension and progression
to a higher blood pressure stage.
42 Finally, the
renineangiotensin system has been proposed to cause
left ventricular hypertrophy and cardiac ﬁbrosis through
mechanisms including blood pressure increase, direct
action of angiotensin II on cardiac myocytes and effects
of aldosterone.
43 Data on these biological factors are not
available for the present study but they merit a separate
follow-up study. Furthermore, our study cannot assess
the speciﬁc pathways that link gout and heart failure,
such as hypertension, atherosclerotic cardiovascular
diseases, drugs, such as anti-inﬂammatories, and renal
dysfunction. I was also unable to tease out the role of
serum urate in gouteheart failure link as it was
measured only in the ﬁrst two cycles.
Heart failure is a major health problem in terms of
morbidity, mortality and costs. This study provides yet
another potentially modiﬁable risk factor for heart
failure. Future studies will need to examine the rela-
tionship between gout severity and heart failure. There
have been numerous studies that have reported
a favourable effect of the gout medication allopurinol
(and its metabolite oxypurinol) on endothelial and
myocardial function among those with hyper-
uricaemia.
11 These molecules have been associated with
improved endothelial function in patients with hyper-
cholesterolaemia,
44 type 2 diabetes with mild hyperten-
sion
45 or chronic heart failure.
12 46 Some studies have
shown an improvement in both LV hypertrophy and
endothelial function due to treatment with allopu-
rinol.
47 48 Other studies have reported improvements in
clinical outcomes of heart failure among patients with
hyperuricaemia upon allopurinol treatment.
11 49 50
Interventional studies might be able to assess whether
allopurinol use can reduce the incidence of heart failure
and subsequent poor outcomes.
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